NASDAQ : YARW
Yarrow Bioscience, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 20 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 186.09M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company’s candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Details
| Name | Yarrow Bioscience, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 7 |
| Founded | 2021 |
| Ceo | Rebecca Velez Frey |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US92941V4077 |
| Cusip | 92941V407 |
| Cik | 1566044 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Rebecca Velez Frey Pharm.D. | President, Chief Executive Officer and Director |
| Tyler Zeronda CPA | Chief Financial Officer |
| Rachael Alford Ph.D. | Chief Operating Officer |
| Dr. Lori Payton Ph.D. | Chief Development Officer |
| Dr. Steven W. Ryder F.A.C.P, M.D. | Chief Medical Officer |
Contact
| Address | 40 10 th Avenue, Floor 7, New York, New York 10014, United States |
| Website | https://www.yarrowbioscience.com |